GlassScriptPhysician profile
Connie Uzel
NPI 1982657755
$8,003.78
in general payments reported to CMS, 2019-2025
67 companies · $919 in 2025
The $919 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $721 · 2020: $633 · 2021: $956 · 2022: $1,647 · 2023: $1,647 · 2024: $1,481 · 2025: $919.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,030 · Education: $17.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,029.53 |
| Education | $17.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $877.34 | 2019-2025 | |
| Celgene Corporation | $536.62 | 2021-2025 | Reblozyl, Pomalyst, Pomalyst |
| Daiichi Sankyo INC. | $418.79 | 2021-2025 | Enhertu |
| Janssen Biotech, INC. | $405.94 | 2019-2025 | Darzalex, Tecvayli, Imbruvica |
| Merck Sharp & Dohme LLC | $396.78 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Astrazeneca Pharmaceuticals LP | $393.67 | 2019-2025 | Calquence, Enhertu, Lynparza |
| Astellas Pharma US INC | $343.91 | 2019-2025 | Xospata, Xtandi, Vyloy |
| Pfizer INC. | $310.49 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $306.52 | 2020-2025 | Libtayo |
| Amgen INC. | $286.67 | 2019-2023 | Nplate, Vectibix, Xgeva |
| Genzyme Corporation | $253.62 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $250.42 | 2019-2025 | Opdivo |
| Incyte Corporation | $229.04 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Eisai INC. | $225.78 | 2021-2025 | |
| Genentech USA, INC. | $195.31 | 2019-2024 | Phesgo, Columvi, Lunsumio |
Show all 67 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Connie Uzel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.